ClinicalTrials.gg

Program

Intravesical Recombinant Mycobacterium (rMBCG)

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms, led by ImmunityBio.

Furthest: phase 2, since Jan 24, 20251 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ImmunityBio11 open or runningphase 2since Jan 24, 2025Jan 24, 2025Feb 2028phase 2 · NCT06800963

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2025First study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsFirst studyNCT06800963 · 40 planned · United States

Ahead

  1. Feb 2028Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06800963

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06800963Non-Muscle Invasive Bladder Neoplasms · United States2RecruitingFeb 202840

How it is read

Names in the registry

  • “Intravesical Recombinant Mycobacterium (rMBCG)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.